These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8212985)

  • 21. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Sandostatin in acromegaly.
    Sassolas G
    Metabolism; 1992 Sep; 41(9 Suppl 2):39-43. PubMed ID: 1518432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide is effective in acromegaly but often results in cholelithiasis.
    Daughaday WH
    Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.
    Catnach SM; Anderson JV; Fairclough PD; Trembath RC; Wilson PA; Parker E; Besser GM; Wass JA
    Gut; 1993 Feb; 34(2):270-3. PubMed ID: 8432484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [99mTc]EHIDA hepatobiliary scan.
    Zhu XF; Harris AG; Yang MF; Shi YF; Zhou Q; Xu JY; Zhang JX
    Dig Dis Sci; 1994 Feb; 39(2):284-8. PubMed ID: 8313809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term treatment with octreotide of patients with acromegaly].
    Weeke J; Orskov H; Christensen SE; Kaal A; Skjaerbaek C; Illum P; Jørgensen J; Lund E; Haubek A; Poulsen JH
    Ugeskr Laeger; 1993 Aug; 155(34):2592-8. PubMed ID: 8212364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.
    Tauber JP; Babin T; Tauber MT; Vigoni F; Bonafe A; Ducasse M; Harris AG; Bayard F
    J Clin Endocrinol Metab; 1989 May; 68(5):917-24. PubMed ID: 2565913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Besser GM; Wass JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):22-33. PubMed ID: 1355588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.
    Stolk MF; van Erpecum KJ; Koppeschaar HP; de Bruin WI; Jansen JB; Lamers CB; van Berge Henegouwen GP
    Gut; 1993 Jun; 34(6):808-13. PubMed ID: 8314514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and tolerability of octreotide treatment in acromegaly.
    Christensen SE; Weeke J; Orskov H; Kaal A; Lund E; Jørgensen J; Harris AG
    Metabolism; 1992 Sep; 41(9 Suppl 2):44-50. PubMed ID: 1518433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective examination of octreotide-induced gall-bladder changes in acromegaly.
    Eastman RC; Arakaki RF; Shawker T; Schock R; Roach P; Comi RJ; Gorden P
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):265-9. PubMed ID: 1563079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event.
    Casagrande A; Bronstein MD; Jallad RS; Moraes AB; Elias PC; Castro M; Czepielewski MA; Boschi A; Ribeiro-Oliveira A; Schweizer JR; Vilar L; Nazato DM; Gadelha MR; Abucham J;
    Neuroendocrinology; 2017; 104(3):273-279. PubMed ID: 27161443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones.
    Veysey MJ; Thomas LA; Mallet AI; Jenkins PJ; Besser GM; Wass JA; Murphy GM; Dowling RH
    Gut; 1999 May; 44(5):675-81. PubMed ID: 10205204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.